ArticleJACC. Case reports2026
Phenotypic Spectrum of Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) is a major determinant of morbidity and mortality and may occur independently of systemic disease activity. CASE SUMMARY: We describe 3 patients with EGPA demonstrating distinct cardiac phenotypes. Patient presentation included: 1) inflammatory cardiomyopathy with severe biventricular dysfunction that improved following escalation of immunosuppression and guideline-directed medical therapy; 2) advanced nonischemic cardiomyopathy and cardiogenic shock requiring temporary and durable mechanical circulatory support, representing an irreversible fibrotic phenotype; and 3) relapsing-remitting eosinophilic perimyocarditis and recurrent ventricular dysfunction despite multiple immunosuppressive regimens. Cardiac magnetic resonance imaging and hemodynamic assessment were central to phenotypic classification and management. DISCUSSION: EGPA cardiomyopathy exists along a spectrum from reversible inflammatory myocarditis to advanced fibrotic remodeling. Cardiac involvement may progress despite improvement in systemic manifestations and is not reliably predicted by antineutrophil cytoplasmic antibody status. TAKE-HOME MESSAGE: Phenotype-based assessment and longitudinal cardiac surveillance may guide immunosuppressive strategies and prognosis in EGPA cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.